SuperworthenGene Therapeutics price to book ratio ENGN
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 0.5×
- 3-year median
- 1.4×
- Against its 3-year history
- 6th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 0.4× to 12.6×
- Peer median
- 1.9×
enGene Therapeutics' price to book ratio is 0.5× as of Oct 23, 2026.
That is below its 3-year median of 1.4×, lower than on 94% of days in the last 3 years.
Over that time it ranged from 0.4× in May 2026 to 12.6× in Mar 2024.
The median for 10 healthcare stocks of a similar size is 1.9×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.5× | 0.4× | 4.9× |
| 2025 | 3.8× | 0.6× | 3.8× |
| 2024 | 1.2× | 1.1× | 12.6× |
Against its peers
Companies in Healthcare nearest enGene Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| ENGNenGene Therapeutics | 0.5× |
| KEQUKewaunee Scientific | 1.3× |
| ICCCImmucell | 3.0× |
| LFVNLifevantage | 2.2× |
| SPROSpero Therapeutics | 1.5× |
| APTAlpha Pro Tech | 0.9× |
| PDEXPro DEX | 4.2× |
| PLXProtalix BioTherapeutics | 2.9× |
| NATRNatures Sunshine Products | 1.3× |
| ELMDElectromed | 4.1× |
| ATNMActinium Pharmaceuticals | 1.6× |
| Peer median | 1.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on enGene Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.